Molgramostim Efficiency Trial in Acute Radiation Damage (Experimental Study)

The purpose of this research was to study the specific activity of the drug molgramostim (Neostim®) under the conditions of a single general γ-irradiation. The antiradiation efficacy of the conducted studies was evaluated, studying the 30-day survival rate and life expectancy of irradiated (at doses of 4, 5, 6, 7, and 8 Gy) mice, as well as the dynamics of peripheral blood and extramedullary and bone marrow hematopoiesis. It has been established that 14-fold (with an interval of 12 h) subcutaneous administration of the drug molgramostim at a dose of 5 μg/kg to mice after irradiation at an average lethal dose (6 Gy) has a pronounced antiradiation effect. The value of the dose modification factor (DMF) when the drug is administered at the optimal dose is 1.16. The use of molgramostim increases the survival rate of mice by 30% and contributes to an earlier, compared with irradiated animals of the control group, restoration of the content of peripheral blood cells (by day 10, the number of leukocytes was 50% more, and the number of lymphocytes, erythrocytes, and platelets was 10% higher than in animals that did not receive the drug), as well as an increase in the number of endogenous CFUs by 30% compared with the control and the number of bone marrow myelokaryocytes by an average of 1.2 times.